American Society of Plastic Surgeons
Log In For Medical Professionals
 

Breast Cancers Detected at Smaller Size in Women with Implants

Breast augmentation with implants does not interfere with the ability to detect later breast cancers—in fact, cancers may detected at a smaller size in breasts with implants, according to a study in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

But mammography may be less likely to detect cancers in breasts with implants, according to the research by Michael Sosin, MD, of MedStar Georgetown University Hospital, Washington, DC, and colleagues. The study also shows some differences in breast cancer diagnosis and treatment in women who have had breast augmentation, including a higher rate of mastectomy.

Palpable Cancers Detected at Smaller Size in Breasts with Implants

The researchers studied 48 patients with breast cancer developing after breast augmentation, along with a group of 302 women with breast cancer who did not have breast implants. Average time from breast augmentation to cancer diagnosis was 14 years. Data on the two groups of patients were analyzed to determine whether and how breast augmentation and the presence of implants affected the detection, staging, and treatment of breast cancer.

At diagnosis, the cancers were significantly smaller in women with breast implants: average size 1.4 centimeter, compared to 1.9 centimeter in women without implants. Of patients whose cancers were detected by the finding of a palpable mass—by either breast self-exam or clinical exam—the average tumor size was 1.6 cm in the breast augmentation group versus 2.33 cm in the comparison group.

However, the rate of cancer detection by screening mammograms was lower for women with implants: 77.8 percent, compared to 90.7 percent in breasts without implants. Cancers tended to be diagnosed at an earlier stage in the breast augmentation group, although the difference was not statistically significant.

The study also found some significant differences in subsequent breast cancer diagnosis and treatment. Women with implants were more likely to undergo excisional biopsy and less likely to undergo imaging-guided core needle biopsy. Women in the breast augmentation group were more likely to be treated with mastectomy, 73 versus 57 percent; and less likely to undergo breast-conserving treatment, 27 versus 43 percent.

Breast cancer detection was unaffected by the type of breast implant (silicone- versus saline-filled), or whether the implant was placed over or under the pectoral muscle. There was some evidence to suggest that mammographic detection was more likely in breasts with saline-filled versus silicone-filled implants.

It's estimated that 1 in 8 women will develop breast cancer during their lives, while almost 300,000 women undergo breast augmentation each year. Studies have clearly shown that breast implants do not increase the risk of breast cancer. But there are continued concerns that implants might lead to delayed diagnosis of breast cancer.

The new findings suggest that breast cancers are likely to be detected at smaller sizes in women who have undergone breast augmentation—especially for palpable masses detected by self-exam or clinical examination. In contrast, screening mammography may be more likely to miss cancers in women with implants, despite the use of modern mammographic techniques designed to increase detection.

While women with implants may be more likely to undergo mastectomy, the authors note that breast-conserving treatment remains an option for such patients. Dr. Sosin comments, "Our findings may have important implications for patient counseling regarding breast augmentation and breast cancer detection."

Plastic and Reconstructive Surgery® is published by Wolters Kluwer.

Click here to read "Breast Cancer following Augmentation Mammaplasty: A Case-Control Study"

Article: "Breast Cancer following Augmentation Mammaplasty: A Case-Control Study" (doi: 10.1097/PRS.0000000000004196)

About Plastic and Reconstructive Surgery

For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. 

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Logo

Patient Care Center